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Letter: immunogenicity of infliximab—ready for routine
prediction? Authors' reply
EDITORS,
We thank Professor Amiot for his interest in our study and his com-

Ultimately, HLA-DQA1*05 genotyping appears to be an important

ments pertaining to the use of HLA-DQA1*05 genotyping for assessing

predictor of infliximab immunogenicity and other outcomes. There

the need for co-immunosuppression.1,2 We agree that immunogenicity

may be benefit for its use for the application of combination therapy or

is not the sole determinant of infliximab loss of response. Other causes

for the withdrawal of the immunomodulator as Professor Amiot sug-

include low drug concentrations and/or exposure due to non-immune

gests. As outlined in our paper, further study is needed to determine

pharmacokinetic mechanisms, activation of non-tumor necrosis

the utility of HLA-DQA1*05 genotyping as a clinically actionable tool.

factor-α pathways and the coexistence of other disease processes such
as irritable bowel syndrome or infection.3-6 In our study, factors affect-

AC K N OW L E D G E M E N T S

ing infliximab exposure such as dose, interval, weight and use of combi-

The authors' declarations of personal and financial interests are un-

nation therapy were accounted for in the multivariable analysis and the

changed from those in the original article. 2

HLA-DQA1*05 genotype remained an independent predictor of loss of
response. Indeed, treatment discontinuation is not synonymous with

LINKED CONTENT

immunogenicity as a multitude of factors may contribute to discon-

This article is linked to Wilson et al and Amiot papers. To view these

tinuation of infliximab over the course of a patient's care. Adverse drug

articles, visit https://doi.org/10.1111/apt.15563 and https://doi.

events, patient preference, loss of response as previously described, in

org/10.1111/apt.15576.

addition to immunogenicity, may all play a role.
Aze Wilson1,2,3

In our data set, co-immunosuppression appeared to reduce the risk
of infliximab anti-drug antibody formation in variant carriers, while hav-

Celeste Peel4

ing little impact on wild-type individuals. Similarly, co-immunosuppres-

Qian Wang5

sion was associated with a reduction in loss of response and treatment

A. Demetri Pananos6

discontinuation in variant carriers, while no apparent difference was

Richard B. Kim1,3

seen in these outcomes between wild type individuals with or with1

out co-immunosuppression. The effect of co-immunosuppression was
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outlined in Tables S2 and S3 of the original manuscript.2 Specifically,
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2

co-immunosuppression was estimated to reduce the risk of infliximab
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loss of response and infliximab treatment discontinuation in variant and
nonvariant carriers by 28% (hazard ratio [HR] = 0.72, 95% confidence

Western University, London, ON, Canada
3
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interval [CI] = 0.43-1.2, P = 0.2) and 27% (HR = 0.73, 95% CI = 0.47-

London, ON, Canada
4

1.13, P = 0.16). A figure that further demonstrates this finding, in terms
of proportion of patients who remain (Figure 1A) or lose response
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(Figure 1B) to infliximab over time is provided as a part of our reply.
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6

These findings did not achieve statistical significance; however, they
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suggest that not everyone benefits from infliximab combination ther-
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apy and that more targeted strategies need to be studied and applied.
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Additionally, we respectfully correct Professor Amiot in his report
of infliximab anti-drug antibody rates in our study population. The rate

ORCID

of infliximab anti-drug antibody formation was 25.4% in variant carriers

Aze Wilson

vs 4.5% in wild-type individuals. Multivariable analysis revealed that

Richard B. Kim

https://orcid.org/0000-0001-6568-1714
https://orcid.org/0000-0001-8148-1632

variant carrier status was highly associated with antibody formation independent of other relevant variables including combination therapy.2
Lastly, we agree that a drug-sensitive ELISA may underestimate
the incidence of anti-drug antibodies in our population; however,
this is the test available to clinicians in practice and thus most closely
mimics the real-world situation.
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F I G U R E 1 Adjusted survival curves of infliximab treatment discontinuation (A) and infliximab loss of response (B) according to
HLADQA1*05A>G genotype and the presence or absence of co-immunosuppression with an immunomodulator (azathioprine or
methotrexate) from a Cox Proportional Hazard Model. Data were adjusted for age, sex, weight and infliximab dose. 95% confidence intervals
are represented by red (HLADQA1*05 wild type and no co-immunosuppression), green (HLADQA1*05 variant and no co-immunosuppression),
blue (HLADQA1*05 wild type and co-immunosuppression) and purple (HLADQA1*05 variant and co-immunosuppression) shading
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